Skip Global navigation and goto content

Monoclonal Antibody Sites Statewide Will Be Closed After FDA Removes Treatment Authorization

Full Story
Tallahassee, Fla. — This evening, without any advanced notice, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorizations (EUA) for bamlanivimab/etesevimab and REGEN-COV. The revised EUAs do not allow providers to administer these treatments within the United States.